Abstract
Abstract. Introduction. Contrast-induced nephropathy is a serious cause of acute kidney injury and represents an urgent problem in clinical practice. Until recently, there are contradictions in the understanding of many aspects of contrast-induced nephropathy. However, the current situation with using CAs in patients with COVID-19, thus causing contrast-induced nephropathy, has become an urgent issue for clinical physicians and radiologists. Aim of this study is to review some up-to-date information on the use of newer and less nephrotoxic drugs among post-COVID-19 patients with a previous renal impairment. Material and Methods. Topical studies published on studying contrast- induced nephropathies in post-COVID-19 patients have been reviewed herein. Results and Discussion. In case of developing the acute renal failure syndrome caused by using CAs in past-COVID-19 patients, first it is necessary to exclude alternative (non-contrast-induced) causes of its occurrence, such as thromboembolism syndrome that may develop upon angiography, ischemic nephropathy, nephrotoxic effects. Upon administration of the X-ray ca, a short-term increase in creatinine levels is possible after 24 hours, but this does not mean the development of contrast-induced nephropathy. Conclusions. To prevent the development of contrast-induced nephropathies, patients must be adequately hydrated. Nephrotoxic drugs should be discontinued at least 24 hours before ca administration. Moreover, the choice of a suitable ca is important.